NorthSea begins intestinal failure associated liver disease therapy trial
NorthSea Therapeutics has commenced a Phase I trial of SEFA-6179 in adult subjects, to obtain a preliminary orphan indication to treat IFALD.
Source: clinicaltrialsarena.com
Stay updated with breaking news from Time Data Services. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
NorthSea Therapeutics has commenced a Phase I trial of SEFA-6179 in adult subjects, to obtain a preliminary orphan indication to treat IFALD.
BerGenBio and Oslo University Hospital executed a collaborative agreement to analyse bemcentinib in a trial in Covid-19 patients.
HDT Bio and Senai Cimatec dosed the first healthy subjects in a Phase I trial of the former’s Covid-19 vaccine, HDT-301, in Brazil.